ALXO News and Press, ALX Oncology Holdings Inc. From 03/08/24

2024-03-08 15:49:00 ET More on ALX Oncology ALX Oncology: Major Caution Warranted Moving Forward Seeking Alpha’s Quant Rating on ALX Oncology Historical earnings data for ALX Oncology Financial information for ALX Oncology Read the full artic...

SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results...

- Investigator-initiated trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma selected for oral presentation SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nas...

2024-01-16 17:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-06 01:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced today that Jason Lettmann, Chief Executive Offi...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2023-12-22 23:22:55 ET Summary ALX Oncology is a biotech focused on developing an anti-CD47 antibody for cancer therapy. The company's pipeline is primarily focused on combination therapies involving evorpacept targeting solid tumors. ALXO announced positive interim findings f...

2023-12-08 17:06:13 ET DENVER, Colo., Dec. 8, 2023 ( www.247marketnews.com )- The following companies published announcements or traded higher-than-usual volume; MBIA (NYSE: MBI), ALX Oncology (NASDAQ: ALXO), SilverSun Technologies (NASDAQ: SSNT), Siyata Mobile (NASDAQ: SYTA), MicroAlgo...

ALX Oncology Holdings Inc. (NASDAQ: ALXO) is one of today's top gainers. The company's shares have moved 2.92% on the day to $6.88. ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ...